Somewhat Favorable News Coverage Somewhat Unlikely to Impact NovoCure Limited (NASDAQ:NVCR) Stock Price
News articles about NovoCure Limited (NASDAQ:NVCR) have trended somewhat positive this week, Accern Sentiment Analysis reports. Accern identifies positive and negative press coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. NovoCure Limited earned a news impact score of 0.00 on Accern’s scale. Accern also gave news stories about the medical equipment provider an impact score of 46.8832319353784 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
These are some of the news stories that may have effected Accern Sentiment’s scoring:
- NovoCure Limited (NasdaqGS:NVCR), iShares Trust – iShares Global 100 ETF (ARCA:IOO) Valuation Takes Center … – Evergreen Caller (evergreencaller.com)
- Wall Street Consensus Watch on NovoCure Limited (NASDAQ:NVCR) – Evergreen Caller (evergreencaller.com)
- Tale of the Ticker: Novocure Ltd (NVCR) Moves on Volume – Stock Press Daily (stockpressdaily.com)
- Mesa Adaptive MA In Focus for Novocure Ltd (NVCR) – Evergreen Caller (evergreencaller.com)
- Novocure to Present at the 2017 Wedbush PacGrow Healthcare Conference (finance.yahoo.com)
NovoCure Limited (NVCR) opened at 18.50 on Monday. The company’s 50-day moving average is $17.97 and its 200-day moving average is $11.61. NovoCure Limited has a 52 week low of $5.95 and a 52 week high of $21.75. The company’s market cap is $1.65 billion.
NovoCure Limited (NASDAQ:NVCR) last announced its quarterly earnings results on Thursday, July 27th. The medical equipment provider reported ($0.24) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.23) by $0.01. The firm had revenue of $38.38 million for the quarter, compared to analysts’ expectations of $42.20 million. NovoCure Limited had a negative net margin of 75.91% and a negative return on equity of 69.48%. On average, analysts anticipate that NovoCure Limited will post ($0.75) EPS for the current fiscal year.
A number of equities analysts have recently commented on the stock. BidaskClub upgraded shares of NovoCure Limited from a “buy” rating to a “strong-buy” rating in a report on Monday, July 31st. Zacks Investment Research lowered shares of NovoCure Limited from a “buy” rating to a “hold” rating in a report on Tuesday, August 1st. Deutsche Bank AG reiterated a “hold” rating and set a $19.00 price target (up previously from $18.00) on shares of NovoCure Limited in a report on Monday, July 17th. ValuEngine upgraded shares of NovoCure Limited from a “sell” rating to a “hold” rating in a report on Saturday, June 3rd. Finally, Wells Fargo & Company upgraded shares of NovoCure Limited from a “market perform” rating to an “outperform” rating and set a $15.00 price target on the stock in a report on Wednesday, May 24th. Three investment analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company’s stock. NovoCure Limited currently has an average rating of “Buy” and an average target price of $19.29.
In other NovoCure Limited news, CEO Asaf Danziger sold 180,601 shares of the stock in a transaction on Monday, June 12th. The shares were sold at an average price of $15.13, for a total transaction of $2,732,493.13. Following the completion of the sale, the chief executive officer now owns 1,163,296 shares of the company’s stock, valued at approximately $17,600,668.48. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Yoram Palti sold 8,000 shares of the stock in a transaction on Friday, May 12th. The shares were sold at an average price of $11.79, for a total transaction of $94,320.00. Following the sale, the insider now directly owns 63,825 shares of the company’s stock, valued at approximately $752,496.75. The disclosure for this sale can be found here. Insiders have sold a total of 2,289,522 shares of company stock valued at $38,762,812 in the last three months. 16.70% of the stock is currently owned by corporate insiders.
About NovoCure Limited
NovoCure Limited is a commercial-stage oncology company. The Company is engaged in developing a cancer treatment centered on a therapy called TTFields, the use of electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. Its TTFields delivery system is used for the treatment of glioblastoma (GBM) and to advance programs testing of TTFields in multiple solid tumor indications through its clinical pipeline.
Receive News & Ratings for NovoCure Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovoCure Limited and related companies with MarketBeat.com's FREE daily email newsletter.